|
|
. |
Pharmacotherapeutic Options for the Treatment of Depression in Patients With Chronic Kidney Disease- Download article and take CE posttest
Colette B. Raymond
Lori D. Wazny
Patricia L. Honcharik
Depressive
disorders occur in up to one-third of patients with chronic kidney
disease CKD). First-line pharmacologic treatments include selective
serotonin reuptake inhibitors and second generation agents, such as
bupropion, mirtazapine, and venlafaxine. Although very little research
has been conducted on the use of antidepressants in CKD, health care
providers should be aware of renal dose adjustments for these agents,
drug interactions, and potential adverse effects. This article reviews
the epidemiology and significance of depression in patients with CKD
and discusses drug therapy options for treatment of depression in this
patient population.
|
| Colette B. Raymond, BScPharm, Pharm D, MSc, ACPR, is
a Clinical Pharmacist, Manitoba Renal Program, Department of
Pharmaceutical Services, Health Sciences Centre Hospital, Winnipeg,
Manitoba, Canada.
Lori D. Wazny, BScPharm, Pharm D, is
a Clinical Pharmacist, Manitoba Renal Program, Department of
Pharmaceutical Services Health Sciences Centre Hospital, Winnipeg,
Manitoba, Canada.
Patricia L. Honcharik, BScPharm, Pharm D, ACPR, is
a Senior Pharmacist, Psychiatry, Department of Pharmaceutical Services,
Health Sciences Centre Hospital, Winnipeg, Manitoba, Canada.
| |
